| Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA CD Siewert, H Haas, V Cornet, SS Nogueira, T Nawroth, L Uebbing, ... Cells 9 (9), 2034, 2020 | 71 | 2020 |
| Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models L Uebbing, L Klumpp, GK Webster, R Löbenberg Drug design, development and therapy 11, 1163, 2017 | 36 | 2017 |
| Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering L Uebbing, A Ziller, C Siewert, MA Schroer, CE Blanchet, DI Svergun, ... Langmuir 36 (44), 13331-13341, 2020 | 33 | 2020 |
| Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy C Wilhelmy, IS Keil, L Uebbing, MA Schroer, D Franke, T Nawroth, M Barz, ... Pharmaceutics 15 (8), 2068, 2023 | 8 | 2023 |
| Gliflozine Hemmstoffe des renalen Glucose-Transporters R Ebert, M Helmstädter, S Stierle, L Uebbing, E Proschak PZ PRISMA 22 (4), 201-212, 2015 | | 2015 |
| Stop the bleeding: Idarucizumab als Dabigatran-Antidot vor der Zulassung B Wagner, M Helmstädter, S Stierle, L Uebbing, R Ebert, M Peknice, ... PHARMAKON 3 (5), 332-334, 2015 | | 2015 |
| Structural and functional characterization of lipid-based mRNA delivery systems LCJ Uebbing Johannes Gutenberg-Universität Mainz, 0 | | |
| Protein Coating of Pharmaceutical Drug Carriers for Specific Cell Targeting T Nawroth, J Al-Gousous, L Krebs, C Siewert, M Klak, L Uebbing, ... | | |
